Literature DB >> 6489415

D-propoxyphene kinetics in man: significance of a deep third compartment.

L F Gram, K Schmidt, F N Christensen, J Schou.   

Abstract

Data from a previously published single dose study of d-propoxyphene 65 mg given i.v. to 8 healthy subjects have been subjected to non linear regression analysis by a curve-fitting program to test the applicability of a 2- and a 3-compartment open model. Analysis of residuals (difference between observed and computed concentrations) revealed similar systematic deviations in all 8 subjects when the 2-compartment model was used (5-10 h negative residuals, after 13 h positive residuals). In contrast, curve-fit by a 3-compartment model (with two parallel peripheral compartments) was good with no systematic deviations. The data show that a terminal monoexponential decline in d-propoxyphene concentrations cannot be expected until 15-30 h after single dose administration, and that the determination of the corresponding half-life is rather inaccurate. Accordingly, precise steady state level predictions may be difficult to obtain from conventional single dose studies with d-propoxyphene.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6489415     DOI: 10.1007/bf00541937

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Concentration of propoxyphene in human plasma following oral, intramuscular, and intravenous administration.

Authors:  R L Wolen; C M Gruber; G F Kiplinger; N E Scholz
Journal:  Toxicol Appl Pharmacol       Date:  1971-07       Impact factor: 4.219

2.  Plasma concentrations of propoxyphene in man. II. Pharmacokinetics.

Authors:  J G Wagner; P G Welling; A J Sedman
Journal:  Int Z Klin Pharmakol Ther Toxikol       Date:  1972-02

3.  Some considerations as to the determination and significance of biologic half-life.

Authors:  M Gibaldi; H Weintraub
Journal:  J Pharm Sci       Date:  1971-04       Impact factor: 3.534

4.  d-Propoxyphene kinetics after single oral and intravenous doses in man.

Authors:  L F Gram; J Schou; W L Way; J Heltberg; N O Bodin
Journal:  Clin Pharmacol Ther       Date:  1979-10       Impact factor: 6.875

5.  A national assessment of propoxyphene in postmortem medicolegal investigation, 1972-1975.

Authors:  B S Finkle; K L McCloskey; G F Kiplinger; I F Bennett
Journal:  J Forensic Sci       Date:  1976-10       Impact factor: 1.832

6.  Cardio-respiratory toxicity of propoxyphene and norpropoxyphene in conscious rabbits.

Authors:  H Lund-Jacobsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-03

7.  Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene.

Authors:  C E Inturrisi; W A Colburn; K Verebey; H E Dayton; G E Woody; C P O'Brien
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

  7 in total
  3 in total

1.  D-Propoxyphene: accumulation or altered kinetics?

Authors:  W A Colburn; C E Inturrisi
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Dextropropoxyphene kinetics after single and repeated oral doses in man.

Authors:  K Brøsen; L F Gram; J Schou; N E Larsen; P Thayssen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  [Sustained-release dextropropoxyphene.].

Authors:  K Kurz-Müller; M Zenz
Journal:  Schmerz       Date:  1991-12       Impact factor: 1.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.